French cancer immunotherapy specialist OSE Pharma prepares IPO

PARIS, Sept 18 (Reuters) - French cancer immunotherapy specialist OSE Pharma has registered with market regulator AMF for an initial public offering (IPO) aimed at financing late-stage trials of its Texopi drug for the most common form of lung cancer, the company said on Thursday.